|
|
Post by peppy on Feb 25, 2022 9:21:44 GMT -5
Ok.. so no word on UT second molecule? I just reread the transcript. Mike did not talk about a UTHR second molecule. What Mike did say regarding UTHR, "There's not much we can do other than continue to feel confident in everything we're doing, be prepared for this, UT's running a great study. They have lots of great data on FDKP and the safety of it. So we feel very good about our response to the FDA and helping UT get this product to finish line. What MannKind is focused on is ensuring commercial product is available upon FDA approval. And we also are anticipating continued expansion of the plant as UT has been running two additional trials for market indications down the road. And we want to make sure that we get well ahead of that in terms of supply and demand. I want to thank everyone for all their help and support over the past year. I apologize about the news this morning." ----------------------------------------------------------------------------------------------------- It looks like UTHR is working to add indications to Tyvasso, one of which is COPD. (?) |
|
|
|
Post by sweedee79 on Feb 25, 2022 9:27:02 GMT -5
Ok.. so no word on UT second molecule? I just reread the transcript. Mike did not talk about a UTHR second molecule. What Mike did say regarding UTHR, "There's not much we can do other than continue to feel confident in everything we're doing, be prepared for this, UT's running a great study. They have lots of great data on FDKP and the safety of it. So we feel very good about our response to the FDA and helping UT get this product to finish line. What MannKind is focused on is ensuring commercial product is available upon FDA approval. And we also are anticipating continued expansion of the plant as UT has been running two additional trials for market indications down the road. And we want to make sure that we get well ahead of that in terms of supply and demand. I want to thank everyone for all their help and support over the past year. I apologize about the news this morning." ----------------------------------------------------------------------------------------------------- It looks like UTHR is working to add indications to Tyvasso, one of which is COPD. (?) Guess I'm confused.. I thought Mnkd 701 was the undisclosed molecule. |
|
|
|
Post by peppy on Feb 25, 2022 9:30:44 GMT -5
I just reread the transcript. Mike did not talk about a UTHR second molecule. What Mike did say regarding UTHR, "There's not much we can do other than continue to feel confident in everything we're doing, be prepared for this, UT's running a great study. They have lots of great data on FDKP and the safety of it. So we feel very good about our response to the FDA and helping UT get this product to finish line. What MannKind is focused on is ensuring commercial product is available upon FDA approval. And we also are anticipating continued expansion of the plant as UT has been running two additional trials for market indications down the road. And we want to make sure that we get well ahead of that in terms of supply and demand. I want to thank everyone for all their help and support over the past year. I apologize about the news this morning." ----------------------------------------------------------------------------------------------------- It looks like UTHR is working to add indications to Tyvasso, one of which is COPD. (?) Guess I'm confused.. I thought Mnkd 701 was the undisclosed molecule. it was dropped..... and it was undisclosed, was it the board that decided it was a second UTHR molecule? I was confused as well. Mike made 701 sound like a distraction they decided to take away. |
|
|
|
Post by cretin11 on Feb 25, 2022 12:45:54 GMT -5
To be fair to whomever transcribed that, MC was speaking very fast and not always clearly. I think the transcriber did a good job but there may be a few words not exactly accurate. In Mike’s defense, he was understandably shook by the news (he apologized for it and said it was not expected). Lots of us have been critical of his stewardship but I couldn’t help feeling for him yesterday as it seems he’d been looking forward to having a rare occasion to celebrate.
|
|
